Industry Outlook 2026: Navigating AI, Sustainability, and Operational Resilience

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

To formulate a definitive roadmap for the pharmaceutical development and manufacturing landscape of 2026, the PharmTech content team connected with more than 30 industry experts, representing a comprehensive cross-section of the industry, including contract research organizations, contract development and manufacturing organizations (CDMOs), specialized manufacturers, genomic sequencing firms, consultants, and scientific AI innovators. These experts revealed that 2026 will be defined by a shift from incremental technological pilots to a profound system-level change.